NO20054440L - Flytende formuleringer av tumornekrosefaktorbindende proteiner - Google Patents

Flytende formuleringer av tumornekrosefaktorbindende proteiner

Info

Publication number
NO20054440L
NO20054440L NO20054440A NO20054440A NO20054440L NO 20054440 L NO20054440 L NO 20054440L NO 20054440 A NO20054440 A NO 20054440A NO 20054440 A NO20054440 A NO 20054440A NO 20054440 L NO20054440 L NO 20054440L
Authority
NO
Norway
Prior art keywords
binding proteins
necrosis factor
tumor necrosis
liquid formulations
factor binding
Prior art date
Application number
NO20054440A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Rita Agostinetto
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20054440L publication Critical patent/NO20054440L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen angår en stabil, farmasøytisk akseptabel, vandig formulering av TNF-bindende protein, som omfatter et TNF-bindende protein, en buffer og et isotonisitetsmiddel.
NO20054440A 2003-02-28 2005-09-26 Flytende formuleringer av tumornekrosefaktorbindende proteiner NO20054440L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100505 2003-02-28
PCT/EP2004/050118 WO2004075918A1 (en) 2003-02-28 2004-02-11 Liquid formulations of tumor necrosis factor-binding proteins

Publications (1)

Publication Number Publication Date
NO20054440L true NO20054440L (no) 2005-09-26

Family

ID=32921619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054440A NO20054440L (no) 2003-02-28 2005-09-26 Flytende formuleringer av tumornekrosefaktorbindende proteiner

Country Status (21)

Country Link
US (3) US8937045B2 (no)
EP (1) EP1603596B1 (no)
JP (1) JP4980048B2 (no)
KR (1) KR20050105486A (no)
CN (1) CN100563712C (no)
AR (1) AR043418A1 (no)
AT (1) ATE394123T1 (no)
BR (1) BRPI0407649A (no)
CA (1) CA2515539A1 (no)
DE (1) DE602004013557D1 (no)
EA (1) EA009079B1 (no)
ES (1) ES2304602T3 (no)
HR (1) HRP20050706A2 (no)
IL (1) IL170414A (no)
MX (1) MXPA05009135A (no)
NO (1) NO20054440L (no)
PL (1) PL213501B1 (no)
RS (1) RS51041B (no)
UA (1) UA82503C2 (no)
WO (1) WO2004075918A1 (no)
ZA (1) ZA200506504B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
MX421100B (es) 2011-07-01 2025-02-10 Biogen Ma Inc Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
EP2919801B1 (en) 2012-10-26 2020-04-29 Lupin Atlantis Holdings, SA Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept
MX2016016148A (es) 2014-06-26 2017-04-25 Maruishi Pharma Preparacion de rocuronio con estabilidad mejorada.
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
ES2171547T3 (es) * 1995-07-14 2002-09-16 Applied Research Systems Receptor de tnf y hormona esteroidica dhea en terapia combinada.
HRP970224A2 (en) * 1996-05-08 1998-04-30 Hoffmann La Roche TREATMENT OF ASTHMA WITH TNFR-Ig
DK0942740T3 (da) * 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM

Also Published As

Publication number Publication date
MXPA05009135A (es) 2005-10-20
UA82503C2 (uk) 2008-04-25
JP2006519210A (ja) 2006-08-24
BRPI0407649A (pt) 2006-02-21
US9512215B2 (en) 2016-12-06
PL213501B1 (pl) 2013-03-29
WO2004075918A1 (en) 2004-09-10
PL378290A1 (pl) 2006-03-20
EA009079B1 (ru) 2007-10-26
AU2004216483A1 (en) 2004-09-10
CA2515539A1 (en) 2004-09-10
RS20050662A (sr) 2007-11-15
AR043418A1 (es) 2005-07-27
RS51041B (sr) 2010-10-31
DE602004013557D1 (de) 2008-06-19
HK1085677A1 (zh) 2006-09-01
JP4980048B2 (ja) 2012-07-18
EP1603596B1 (en) 2008-05-07
ZA200506504B (en) 2006-12-27
US20150098950A1 (en) 2015-04-09
CN100563712C (zh) 2009-12-02
IL170414A (en) 2009-11-18
ES2304602T3 (es) 2008-10-16
HRP20050706A2 (en) 2005-12-31
EA200501230A1 (ru) 2006-04-28
US20170020960A1 (en) 2017-01-26
US8937045B2 (en) 2015-01-20
KR20050105486A (ko) 2005-11-04
EP1603596A1 (en) 2005-12-14
US20070053906A1 (en) 2007-03-08
ATE394123T1 (de) 2008-05-15
CN1774266A (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
ZA200309460B (en) Novel Benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl trasferase proteins.
SV2006002174A (es) Composicion de anticuerpo her2
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
DE60322720D1 (de) Feste formulierungen enthaltend eine indolinon verbindung
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
WO2005018605A3 (en) Novel formulation of ropinirole
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
NO20065860L (no) Stabiliserte flytende interferonformuleringer
NO20042563L (no) Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application